Geron Corp

NASDAQ:GERNUnited States

Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.

Contact Information

Headquarters

919 East Hillsdale Boulevard, Suite 250FOSTER CITY, CA, United States 94404

Phone

650-473-7700

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer

John Scarlett

Chief Financial Officer, Executive Vice President - Finance, Treasurer

Michelle Robertson

Executive Vice President, Chief Operating Officer

Andrew Grethlein

Chief People Officer, Senior Vice President

Shannon Odam

Executive Vice President, Chief Legal Officer, Secretary

Scott Samuels